Table 3

Results of patient-reported outcomes—PFDI-SF20, PFIQ-7 and PISQ-12

Outcome measure
Timepoint
Oestrogen
N; mean (SD)
No treatment
N; mean (SD)
Mean difference between groups (95% CI)‡
PFDI-SF20; POPDI-6 domain (0–100, higher=worse pain)*
 Baselinen=48;n=49;
43.4 (24.8)46.0 (24.4)
 6 monthsn=38;n=41;4.1 (−3.9 to 12.1)
16.3 (20.3)12.5 (11.6)
 12 monthsn=37;n=41;4.4 (−4.7 to 13.5)
16.7 (20.6)14.6 (15.6)
PFDI-SF20; CRADI-8 domain (0–100, higher=worse pain)*
 Baselinen=48;n=48;
26.0 (25.0)24.3 (18.0)
 6 monthsn=38;n=41;−2.4 (−7.6 to 3.4)
12.7 (14.4)15.2 (13.2)
 12 monthsn=37;n=42;−1.7 (−8.0 to 4.6)
12.8 (14.8)15.8 (15.8)
PFDI-SF20; UDI-6 domain (0–100, higher=worse pain)*
 Baselinen=48;n=49;
34.8 (22.6)37.9 (26.7)
 6 monthsn=38;n=41;0.5 (−8.9 to 7.9)
16.4 (17.5)17.2 (18.5)
 12 monthsn=36;n=42;0.7 (−9.1 to 10.4)
20.3 (17.5)21.5 (25.3)
PFDI-SF20; summary score (0–300, higher=worse pain)*
 Baselinen=48;n=48;
104.3 (62.8)107.0 (57.4)
 6 monthsn=38;n=41;0.6 (−18.4 to 17.2)
45.4 (43.8)45.0 (37.1)
 12 monthsn=36;n=41;4.8 (−16.2 to 25.8)
49.8 (44.1)51.1 (47.7)
PFIQ-7; UIQ-7 domain (0–100, higher=worse condition)*
 Baselinen=50;n=50;
21.0 (25.8)21.5 (24.6)
 6 monthsn=38;n=41;1.3 (−6.9 to 9.5)
9.6 (21.7)5.9 (11.2)
 12 monthsn=37;n=42;1.4 (−6.0 to 8.8)
8.9 (16.8)8.0 (13.9)
PFIQ-7; CRAIQ-7 domain (0–100, higher=worse condition)*
 Baselinen=50;n=50;
12.0 (21.0)8.7 (13.5)
 6 monthsn=38;n=41;1.6 (−2.5 to 5.8)
4.9 (13.1)2.4 (6.1)
 12 monthsn=36;n=42;2.2 (−2.8 to 7.1)
4.5 (16.3)2.9 (6.1)
PFIQ-7; POPIQ-7 domain (0–100, higher=worse condition)*
 Baselinen=50;n=50;
17.7 (21.2)17.1 (22.1)
 6 monthsn=38;n=41;2.5 (−2.5 to 7.5)
5.0 (13.4)2.3 (6.1)
 12 monthsn=36;n=42;0.2 (−2.7 to 3.1)
1.9 (6.8)1.7 (5.2)
PFIQ-7; summary score (0–300, higher=worse pain)*
 Baselinen=50;n=50;
50.8 (54.8)47.3 (51.9)
 6 monthsn=38;n=41;6.2 (−8.7 to 21.2)
19.5 (39.8)10.7 (19.8)
 12 monthsn=36;n=42;4.5 (−6.8 to 15.8)
14.3 (29.1)12.7 (18.3)
PISQ-12 (0–48, higher=better sexual function)†
 Baselinen=18;n=19;
31.2 (6.5)33.1 (7.3)
 6 monthsn=11;n=14;−2.4 (−7.0, 2.2)
33.1 (4.1)36.1 (5.7)
 12 monthsn=11;n=10;3.4 (0.6 to 6.2)
34.5 (2.7)32.8 (5.1)
  • *<0 indicates less pain/better condition failures with oestrogen.

  • †>0 indicates better with oestrogen.

  • ‡Differences are adjusted for baseline score and minimisation variables.

  • CRADI-8, Colorectal-Anal Distress Inventory; CRAIQ-7, Colorectal-Anal Impact; PFDI-SF20, Pelvic Floor Distress Inventory Short Form 20; PFIQ-7, Pelvic Floor Impact Questionnaire; PISQ-12, Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire; POPDI-6, Pelvic Organ Prolapse Distress Inventory; UDI-6, Urinary Distress Inventory.